Improving Graft-Versus-Host Disease Prevention After Haploidentical HSCT
Seeking to improve graft-versus-host disease (GVHD) prophylaxis in haploidentical (HI) hematopoietic stem cell transplant (HSCT), researchers investigated a regimen of post-transplant cyclophosphamide (PTCy), abatacept (A), and a short course of tacrolimus (CAST). In a presentation of the findings at the Transplantation & Cellular Therapy 2022 Tandem Meetings, A. Samer Al-Homsi and colleagues suggested that “CAST with shortened course of T is feasible and offers promising outcomes with low rates of acute GVHD.” ...
Advertisement
Advertisement
Advertisement
Advertisement